Table 1. Literature reporting granulocytic sarcoma complicating Essential Thrombocythemia

Authors	Age sex	Delay before SG transformation	ET treatment	Locations	Immunohistochemistry	AML	SG  Traitement	SG evolution
Au WY      2000 ^4	55/F	84 months	Melphalan, hydroxyurea	left parietal bone	CD31, CD34	AML	UK	UK
Famoso G  2006 ^5	68/M	60 months	Hydroxyurea	Muscle, left hip	CD43, CD45, CD34, factor VIII, CD 117, Vimentin,  EMA, CD68	AML7	Aracytin low dose	1 month, death by pneumopathy
Tanaka Y  2006 ^8	59/F*	204 months	Hydroxyurea, busulfan, mitobronitol, ranimustine	Left hip, skin, liver and spleen	CD13, CD33, CD34, CD117	AML2	Imatinib, aracytin and etoposide	7 months, death by pneumopathy
Shikata H  2009 ^7	72/M	72 months	Hydroxyurea	Stomach, lung and spleen	CD13, HLA-DR, CD34, CD117	AML	UK	5 months, death by pneumopathy
Desplechin A, 2010 ^6	80/M**	72 months	Pipobroman, Anti platelet agregation	Left hip	UK	AML7	UK	4 months, evolution UK
Our case   2011	57/F	12 months	Hydroxyurea pipobroman, anagrelide	Sternum,  mandible, femur	CD34, CD31, EMA,  MPO, lysozyme, factor VIII.	AML7	Aracytin, idarubicine, etopisde, and mitoxantrone-aracytine	5 months, death by pneumopathy

* : Secondary fibrosis; ** : Jak 2 mutation. Abbreviations:  MPO, myeloperoxydase;  UK, unknown.